Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle
domain framework. Since their introduction 20 years ago as an alternative to antibodies for …

Introduction: The integration of diagnostic testing for the presence of a molecular target is of
interest to predict successful targeted radionuclide therapy (TRNT). This so-called …

The success of protein engineering and design has extensively expanded the protein space,
which presents a promising strategy for creating next-generation proteins of diverse …

RIT has become an attractive strategy in cancer treatment, but still faces important
drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting …

The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is
of increasing importance with the recent approval of more efficacious HER2-targeted …

Targeted radionuclide therapy (TRT) is an emerging field and has the potential to become a
major pillar in effective cancer treatment. Several pharmaceuticals are already in routine use …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

Purpose A novel HER2 affibody-based molecular probe,[18F] AlF-RESCA-HER2-BCH, was
developed for reducing renal uptake, evaluated, and compared with [18F] AlF-NOTA-HER2 …

Affibody molecules are small and robust non-immunoglobulin affinity ligands capable of
binding to a wide range of protein targets. They are selected from combinatorial libraries …

Technetium-99m, the most commonly used radionuclide in nuclear medicine, can be
attached to biologically important molecules through a variety of chelating agents, the choice …